Paul and Mira Sorvino Announce Nationwide Recipe Contest
Diabetes Co-Stars: Cook-Off Invites People to Share Diabetes-Friendly Recipes
Bridgewater, N.J., June 7, 2011 /PRNewswire/ — Actors Paul and Mira Sorvino today announce the Diabetes Co-Stars: Cook-Off. This nationwide recipe contest runs from June 7-July 20, 2011 and is a continuation of their work with sanofi-aventis U.S. on the Diabetes Co-Stars awareness campaign, which is designed to help educate people living with diabetes and those who support them.
“As a connoisseur of good food, and someone living with diabetes, I understand the importance of creating meals that my whole family can enjoy,” says Paul, “which is why I’m eager to prepare new diabetes-friendly recipes with the contestants.”
Paul is living with type 2 diabetes and currently uses Lantus® SoloSTAR® (insulin glargine [rDNA origin] injection) as part of his overall diabetes treatment plan. His daughter Mira provides him with support as the “co-star” on his journey and inspires supporters of people living with diabetes to learn more about the condition.
“Dad and I have had a wonderful experience partnering with sanofi-aventis U.S. on the Diabetes Co-Stars campaign, and we are very excited to continue our outreach,” says Mira. “Our family recognizes the importance of support in a diabetes treatment plan, and we hope to share our story with more of the 26 million Americans who are living with diabetes and their loved ones.”
People living with diabetes and those who support them are invited to submit an original diabetes-friendly recipe at www.DiabetesCoStars.com. Recipes will be selected based on creativity, whether or not it is diabetes-friendly as determined by a dietician, and how easy it is to follow. Two finalists will be selected and brought to New York City to compete against one another in a cook-off at the Food Network New York City Wine & Food Festival on September 30, 2011. Paul and Mira will assist the finalists in the preparations and festival goers will select the winning dish. To learn how to enter the contest and view official rules visit www.DiabetesCoStars.com. Finalists will be announced on August 30, 2011 on the campaign website and sanofi-aventis U.S. Diabetes social media pages.
On www.DiabetesCoStars.com people living with diabetes, family
and friends can view Paul and Mira’s story and find advice on
lifestyle choices, healthy cooking, physical activity and treatment
options including insulin. The site also provides links to the
sanofi-aventis U.S. Diabetes social media web pages, including the
sanofi-aventis U.S. Diabetes Facebook page and Twitter feed.
Indications and Usage
Prescription Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and children (6 years and older) with type 1 diabetes for the control of high blood sugar. It should be taken once a day at the same time each day to lower blood glucose.
Do not use LANTUS® to treat diabetic ketoacidosis.
Important Safety Information for Lantus®
Do not take Lantus if you are allergic to insulin or any of the inactive ingredients in Lantus. You must test your blood sugar levels while using insulin, such as Lantus. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision.
Do NOT dilute or mix Lantus with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Lantus must only be used if the solution is clear and colorless with no particles visible. Do not share needles, insulin pens or syringes with others.
The most common side effect of insulin, including Lantus, is low blood sugar (hypoglycemia), which may be serious. Some people may experience symptoms such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia may be serious and life threatening. It may cause harm to your heart or brain. Other possible side effects may include injection site reactions, including changes in fat tissue at the injection site, and allergic reactions, including itching and rash. In rare cases, some allergic reactions may be life threatening.
Tell your doctor about other medicines and supplements you are taking because they can change the way insulin works. Before starting Lantus, tell your doctor about all your medical conditions including if you have liver or kidney problems, are pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed.
Lantus SoloSTAR is a disposable prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.
For Full Prescribing Information for Lantus® please visit
www.Lantus.com or call 1-800-633-1610.
Diabetes is a chronic, widespread condition in which the body
does not produce or properly use insulin, the hormone needed to
transport glucose (sugar) from the blood into the cells of the body
for energy. More than 230 million people worldwide are living with
the disease and this number is expected to rise to a staggering 350
million within 20 years. It is estimated that nearly 26 million
Americans have diabetes, including an estimated 7 million who
remain undiagnosed. At the same time, approximately 40 percent of
those diagnosed are not achieving the blood sugar control target of
A1C <7 percent recommended by the American Diabetes Association
(ADA). The A1C test measures average blood glucose levels over the
past two-to three-month period.
About the Sanofi Diabetes Division
Sanofi strives to help people manage the complex challenges of
diabetes by delivering innovative, integrated and personalized
solutions. Driven by valuable insight that comes from listening to
and engaging with people living with diabetes, the Company is
forming partnerships to offer diagnostics, therapies, services, and
devices. Sanofi markets both injectable and oral medications for
people with type 1 or type 2 diabetes. Investigational compounds in
the pipeline include an injectable GLP-1 agonist being studied as a
single agent, in combination with basal insulins, and/or in
combination with oral antidiabetic agents.
About sanofi-aventis U.S.
Sanofi-aventis U.S. is part of Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Posted: June 2011